SCHRODINGER INC

SDGRNASDAQ

🏆 #2044 by market capEarnings Nov 4US Equity

$18.51▼ $0.14 (−0.75%)

Live

1h▲ 0.8%

24h▼ 0.8%

7d▲ 12.7%

14d▲ 22.5%

30d▲ 12.9%

1y▼ 1.8%

🏦Market Cap

$1.38B

Small Cap

📈Revenue Growth (YoY)

+23.3%

Healthy

📊Gross Margin

56.9%

Healthy

💵FCF Margin

-12.5%

Thin

⚖️P/S Ratio

5.4x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $18.42 – $18.75
52-Week Range: $10.95 – $23.02
Volume: $2.31B
Avg Volume: $1.80B
Shares Outstanding: 74.7M
Next Earnings: Oct 15, 2026

Fundamentals Snapshot

Annual Revenue: $256M
Last Q Revenue: $59M
P/E Ratio: -25.2
P/S Ratio: 5.4x
EPS (TTM): $-0.73
Dividend Yield: 0.00%

Why Investors Own SDGR

✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
✓Healthy economics — 31% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$256M▼ −12.5% YoY

Gross Margin (TTM)

31.2%▲ +1.0% YoY

Operating Income (TTM)

$49M▼ −12.5% YoY

Free Cash Flow (TTM)

$62M▼ −12.5% YoY

About SCHRODINGER INC

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

🦦